PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Abrocitinib Suspension F2
Drug: Abrocitinib Suspension F5
Drug: Abrocitinib Suspension F3
Drug: Abrocitinib Suspension F4
Drug: Abrocitinib Suspension F6
Drug: Abrocitinib Suspension F1
Drug: Abrocitinib tablet
Drug: Famotidine

First Posted Date: 2021-05-26

Last Posted Date: 2024-11-14

Lead Sponsor: Pfizer

Target Recruit Count: 19

Registration Number: NCT04903093

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age

Phase 4

Completed

Conditions: Meningococcal Vaccine

Interventions: Biological: Trumenba

First Posted Date: 2021-05-20

Last Posted Date: 2024-10-16

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT04893811

Locations: 🇵🇱
IN-VIVO Sp. z o.o., Bydgoszcz, Poland
🇵🇱
Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o., Krakow, Poland
🇵🇱
WIP Warsaw IBD Point Profesor Kierkus, Warszawa, Poland

and more 7 locations

A Study Comparing Subcutaneous Injection of Sayana Press In the Upper Arm Versus Anterior Thigh and Abdomen

Phase 1

Recruiting

Conditions: Healthy

Interventions: Combination Product: Sayana Press

First Posted Date: 2021-05-20

Last Posted Date: 2024-10-07

Lead Sponsor: Pfizer

Target Recruit Count: 68

Registration Number: NCT04893798

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: PF-06882961
Drug: Placebo

First Posted Date: 2021-05-17

Last Posted Date: 2024-09-30

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT04889157

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China

A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

Not yet recruiting

Conditions: Metastatic Kidney Cancer
Epithelial Ovarian Cancer
Non-small Cell Lung Cancer
Metastatic Colorectal Cancer
Cervical Cancer
Metastatic Breast Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: Zirabev

First Posted Date: 2021-05-17

Last Posted Date: 2024-11-04

Lead Sponsor: Pfizer

Target Recruit Count: 400

Registration Number: NCT04889495

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

Phase 3

Completed

Conditions: Pneumococcal Disease
SARS-CoV-2 Infection
COVID-19

Interventions: Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological: BNT162b2
Other: Saline

First Posted Date: 2021-05-14

Last Posted Date: 2022-12-14

Lead Sponsor: Pfizer

Target Recruit Count: 570

Registration Number: NCT04887948

Locations: 🇺🇸
Aventiv Research Inc, Columbus, Ohio, United States
🇺🇸
Acevedo Clinical Research Associates, Miami, Florida, United States
🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

and more 21 locations

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck
Ovarian Cancer
Non-Small Cell Lung Cancer

Interventions: Biological: PF-07257876

First Posted Date: 2021-05-11

Last Posted Date: 2024-04-03

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT04881045

Locations: 🇺🇸
Siteman Cancer Center - St Peters, Saint Peters, Missouri, United States
🇪🇸
Hospital General Universitario Gregorio Marañon, Madrid, Madrid, Comunidad DE, Spain
🇺🇸
The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate (Emergency Back-Up Only), Santa Monica, California, United States

and more 38 locations

Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

Phase 4

Completed

Conditions: Hospital Acquired Pneumonia
Acute Pyelonephritis
Intra-abdominal Infection
Bacteremia
Urinary Tract Infection
Ventilator-associated Pneumonia

Interventions: Drug: Zavicefta, Ceftazidime-Avibactam
Drug: Best Available Treatment

First Posted Date: 2021-05-11

Last Posted Date: 2024-10-21

Lead Sponsor: Pfizer

Target Recruit Count: 60

Registration Number: NCT04882085

Locations: 🇨🇳
Chizhou People's Hospital, Chizhou, Anhui, China
🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳
The First Affiliated Hospital of Bengbu Medical, Bengbu, Anhui, China

and more 32 locations

Special Investigation of COMIRNATY in the Population With Underlying Diseases

Completed

Conditions: COVID-19

Interventions: Biological: BNT162b2

First Posted Date: 2021-05-10

Last Posted Date: 2024-06-21

Lead Sponsor: Pfizer

Target Recruit Count: 1075

Registration Number: NCT04880447

Locations: 🇯🇵
Pfizer Local County, Tokyo, Japan

Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia

Phase 1

Completed

Conditions: Severe Hemophilia

Interventions: Biological: PF-06741086

First Posted Date: 2021-05-07

Last Posted Date: 2023-07-07

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT04878731

Locations: 🇨🇳
Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy